Brofaromine in Panic Disorder: A Pilot Study with a New Reversible Inhibitor of Monoamine Oxidase-A

Publisher Website
Google Scholar
Abstract
The therapeutic efficacy of brofaromine - a new reversible and short acting MAO-A inhibitor - was evaluated in 14 inpatients with a panic disorder In an open trial, the patients were treated with placebo during the first week and with 150mg brofaromine per day during the following four weeks. In all patients a distinct improvement in both anxiety and depressive symptoms was observed under the active drug. Treatment outcome was the same in patients with and without a concomitant major depressive episode. No side effects of any note were reported. Our findings suggest that the MAO-A inhibitor brofaromine is an effective drug in the treatment of anxiety disorders.

This publication has 0 references indexed in Scilit: